Pfizer and BioNTech have signed a letter of intent with Biovac, a Cape City-based biopharmaceutical firm, to fabricate the Pfizer-BioNTech Covid-19 vaccine for distribution inside the African Union.
To facilitate Biovac’s involvement within the course of, technical switch, on-site growth and tools set up actions will start instantly, Pfizer stated in a press assertion on Wednesday (21 July).
Pfizer and BioNTech stated they count on that Biovac’s Cape City facility can be integrated into the vaccine provide chain by the tip of 2021.
Biovac will get hold of drug substances from services in Europe, and manufacturing of completed doses will start in 2022.
At full operational capability, the annual manufacturing will exceed 100 million completed doses yearly and all doses will solely be distributed inside the 55 member states that make up the African Union.
“From day one, our purpose has been to supply truthful and equitable entry of the Pfizer-BioNTech Covid-19 Vaccine to everybody, all over the place,” stated Albert Bourla, chief govt of Pfizer.
“Our newest collaboration with Biovac is a shining instance of the tireless work being executed, on this occasion to profit Africa.
“We are going to proceed to discover and pursue alternatives to deliver new companions into our provide chain community, together with in Latin America, to additional speed up entry of Covid-19 vaccines.”
Biovac is aiming to begin manufacturing of the mRNA Covid-19 vaccine within the second half of subsequent 12 months, its chief govt officer Morena Makhoana instructed Reuters.
Makhoana stated that the agency would ramp up manufacturing of the Covid-19 vaccine earlier than reaching output of 100 million doses a 12 months round early 2023.